Several other frameworks were also proposed for standardized interpretation of PSMA-PET/CT imaging, such as the EANM Delphi consensus from 2017, which was updated to E-EANM or the “Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE)” from 2018, which defines molecular imaging TNM (miTNM) regions and subregions for whole-body staging, similar to the pathological/clinical TNM system and the PRIMARY score by Emmett et al assessing patterns of intra-prostatic PSMA [10–13, 32]. This evidence concerns the gene FOLH1 and Familial prostate cancer.